| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
O-Succinylhomoserine is a substrate for cystathionine γ-synthase, the enzyme that catalyzes the first committed step in the transsulfuration pathway of methionine biosynthesis. In this pathway, O-succinylhomoserine reacts with cysteine to form cystathionine, which is subsequently cleaved to yield homocysteine and then methionine. The compound does not have a direct pharmacological target in mammalian systems but is a key metabolite in bacterial sulfur amino acid metabolism. Its role is primarily biochemical rather than therapeutic.
|
|---|---|
| ln Vitro |
O-Succinylhomoserine serves as the native, kinetically preferred substrate for cystathionine γ-synthase in Gram-negative facultative anaerobes, with an 8.2-fold activity preference over alternative esters such as O-acetylhomoserine. In fermentation processes, yields of up to 121.7 g/L have been achieved for coupled L-methionine and succinic acid co-production. The compound's role in bacterial metabolism makes it a target for metabolic engineering to enhance methionine production.
|
| ln Vivo |
O-Succinylhomoserine is an intermediate in bacterial methionine biosynthesis and is not a therapeutic agent. It has been studied in the context of metabolic engineering and industrial fermentation for the production of methionine and other sulfur-containing amino acids. In vivo studies are primarily focused on bacterial systems rather than animal models. Its biological activity is limited to its role as a metabolic intermediate in microorganisms.
|
| Enzyme Assay |
In vitro enzyme assays for O-succinylhomoserine involve measuring the activity of cystathionine γ-synthase using O-succinylhomoserine as the substrate. The assay typically includes the enzyme, O-succinylhomoserine, and cysteine, with the formation of cystathionine monitored by HPLC or by following the release of succinate. Kinetic parameters such as Km and Vmax are determined from substrate saturation curves. These assays are used to characterize enzyme specificity and to screen for inhibitors of bacterial methionine biosynthesis.
|
| Cell Assay |
Cellular assays for O-succinylhomoserine are not typically performed in mammalian cell lines, as the compound is a bacterial metabolite. In bacterial systems, E. coli or S. typhimurium cultures are grown in minimal media supplemented with O-succinylhomoserine or its precursors. Methionine auxotrophy assays can be used to assess the compound's ability to support bacterial growth. Metabolic flux analysis may be performed using isotope-labeled O-succinylhomoserine to trace its incorporation into methionine and other metabolites.
|
| Animal Protocol |
O-Succinylhomoserine is not administered to animals as a drug and therefore lacks conventional in vivo animal study protocols. However, it may be used in animal nutrition studies to assess methionine metabolism or in models of bacterial infection to evaluate the role of the methionine biosynthesis pathway in bacterial pathogenesis. Metabolic studies in rodents could involve the administration of labeled O-succinylhomoserine to trace its metabolic fate, though such studies are uncommon.
|
| ADME/Pharmacokinetics |
O-Succinylhomoserine is a polar, water-soluble compound that is a normal intermediate in bacterial metabolism. It is not a drug and therefore has not been characterized in terms of mammalian pharmacokinetics. In bacterial cells, it is rapidly converted to cystathionine by cystathionine γ-synthase. Its stability in biological systems is limited by its enzymatic conversion. For research use, the compound is typically stored as a solid powder at -20°C for long-term stability.
|
| Toxicity/Toxicokinetics |
O-Succinylhomoserine is a normal metabolic intermediate and is not considered toxic. It is produced endogenously in bacteria and is not administered as a drug to humans or animals. In the context of industrial fermentation, high concentrations of O-succinylhomoserine may be tolerated by bacterial production strains. No specific toxicity data are available for this compound, as it is not intended for therapeutic use.
|
| References | |
| Additional Infomation |
O-Succinyl-L-homoserine is an O-succinyl derivative of L-homoserine. It is a metabolite of both Saccharomyces cerevisiae and Escherichia coli. It is a hemisuccinic acid and also an O-succinylhomoserine. It is the conjugate acid of O-succinyl-L-homoserine (1-). O-Succinyl-L-homoserine is a metabolite found or produced by Escherichia coli (K12 strain, MG1655 strain). It has been reported to exist in Daphnia frenulum, Apis cerana, and some other organisms with relevant data. O-Succinyl-L-homoserine is a metabolite found or produced by Saccharomyces cerevisiae.
O-Succinylhomoserine is an important intermediate in bacterial methionine biosynthesis and has applications in metabolic engineering and industrial biotechnology. It is used in the production of methionine and other sulfur-containing amino acids through fermentation processes. The compound is not a therapeutic agent and has no clinical indications. Its role as a substrate for cystathionine γ-synthase makes it a target for the development of antibacterial agents that inhibit methionine biosynthesis. Research continues to explore its utility in synthetic biology and industrial microbiology. |
| Molecular Formula |
C8H13NO6
|
|---|---|
| Molecular Weight |
219.19
|
| Exact Mass |
219.074
|
| CAS # |
1492-23-5
|
| PubChem CID |
439406
|
| Appearance |
White to off-white solid powder
|
| Density |
1.392g/cm3
|
| Boiling Point |
492.8ºC at 760mmHg
|
| Flash Point |
251.8ºC
|
| Vapour Pressure |
4.68E-11mmHg at 25°C
|
| Index of Refraction |
1.515
|
| LogP |
-3.7
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
15
|
| Complexity |
252
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(COC(=O)CCC(=O)O)[C@@H](C(=O)O)N
|
| InChi Key |
GNISQJGXJIDKDJ-YFKPBYRVSA-N
|
| InChi Code |
InChI=1S/C8H13NO6/c9-5(8(13)14)3-4-15-7(12)2-1-6(10)11/h5H,1-4,9H2,(H,10,11)(H,13,14)/t5-/m0/s1
|
| Chemical Name |
(2S)-2-amino-4-(3-carboxypropanoyloxy)butanoic acid
|
| Synonyms |
O-Succinyl-L-homoserine; O-Succinylhomoserine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~17.86 mg/mL (~81.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5623 mL | 22.8113 mL | 45.6225 mL | |
| 5 mM | 0.9125 mL | 4.5623 mL | 9.1245 mL | |
| 10 mM | 0.4562 mL | 2.2811 mL | 4.5623 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
